May 1 (Reuters) - Nexalin Technology Inc NXL.O:
NEXALIN TECHNOLOGY INITIATES FDA Q-SUBMISSION PROCESS FOR GEN-2 SYNC FOLLOWING ENCOURAGING DATA AND PRELIMINARY FDA FEEDBACK
NEXALIN TECHNOLOGY INC - Q-SUBMISSION TO FACILITATE DIALOGUE WITH FDA ON CLINICAL TRIAL DESIGN
Source text: ID:nGNX1pt4Nv
Further company coverage: NXL.O
((Reuters.Briefs@thomsonreuters.com))